FDA Approves Pritelivir, First Oral Antiviral for Resistant Herpes in 30 Years

The FDA approved pritelivir, a novel oral antiviral for immunocompromised patients with acyclovir-resistant herpes simplex virus, marking the first new drug class for this indication in nearly three decades. The approval addresses an unmet medical need in a niche but vulnerable population, though its market impact is limited by the narrow target population.